TY  - JOUR
AU  - Zamboglou, Constantinos
AU  - Peeken, Jan C
AU  - Janbain, Ali
AU  - Katsahian, Sandrine
AU  - Strouthos, Iosif
AU  - Ferentinos, Konstantinos
AU  - Farolfi, Andrea
AU  - Koerber, Stefan A
AU  - Debus, Juergen
AU  - Vogel, Marco E
AU  - Combs, Stephanie E
AU  - Vrachimis, Alexis
AU  - Morganti, Alessio Giuseppe
AU  - Spohn, Simon K B
AU  - Shelan, Mohamed
AU  - Aebersold, Daniel M
AU  - Grosu, Anca-Ligia
AU  - Ceci, Francesco
AU  - Henkenberens, Christoph
AU  - Kroeze, Stephanie G C
AU  - Guckenberger, Matthias
AU  - Fanti, Stefano
AU  - Belka, Claus
AU  - Bartenstein, Peter
AU  - Hruby, George
AU  - Scharl, Sophia
AU  - Wiegel, Thomas
AU  - Emmett, Louise
AU  - Arnoux, Armelle
AU  - Schmidt-Hegemann, Nina-Sophie
TI  - Development and Validation of a Multi-institutional Nomogram of Outcomes for PSMA-PET-Based Salvage Radiotherapy for Recurrent Prostate Cancer.
JO  - JAMA network open
VL  - 6
IS  - 5
SN  - 2574-3805
CY  - Chicago, Ill.
PB  - American Medical Association
M1  - DKFZ-2023-01034
SP  - e2314748
PY  - 2023
AB  - Prostate-specific antigen membrane positron-emission tomography (PSMA-PET) is increasingly used to guide salvage radiotherapy (sRT) after radical prostatectomy for patients with recurrent or persistent prostate cancer.To develop and validate a nomogram for prediction of freedom from biochemical failure (FFBF) after PSMA-PET-based sRT.This retrospective cohort study included 1029 patients with prostate cancer treated between July 1, 2013, and June 30, 2020, at 11 centers from 5 countries. The initial database consisted of 1221 patients. All patients had a PSMA-PET scan prior to sRT. Data were analyzed in November 2022.Patients with a detectable post-radical prostatectomy prostate-specific antigen (PSA) level treated with sRT to the prostatic fossa with or without additional sRT to pelvic lymphatics or concurrent androgen deprivation therapy (ADT) were eligible.The FFBF rate was estimated, and a predictive nomogram was generated and validated. Biochemical relapse was defined as a PSA nadir of 0.2 ng/mL after sRT.In the nomogram creation and validation process, 1029 patients (median age at sRT, 70 years [IQR, 64-74 years]) were included and further divided into a training set (n = 708), internal validation set (n = 271), and external outlier validation set (n = 50). The median follow-up was 32 months (IQR, 21-45 months). Based on the PSMA-PET scan prior to sRT, 437 patients (42.5
LB  - PUB:(DE-HGF)16
C6  - pmid:37219907
DO  - DOI:10.1001/jamanetworkopen.2023.14748
UR  - https://inrepo02.dkfz.de/record/276223
ER  -